IGLL1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10308(IGLL1 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

**Background of IGLL1 Antibody**

The IGLL1 (Immunoglobulin Lambda Like Polypeptide 1) gene encodes a critical component of the pre-B cell receptor (pre-BCR), a structure essential for early B cell development. Expressed predominantly in precursor B cells, IGLL1 (also known as λ5) pairs with the surrogate light chain (VpreB) and the heavy chain (μ) to form the pre-BCR, which drives proliferation and differentiation of pre-B cells into immature B cells. Dysregulation of IGLL1 is linked to immunodeficiencies, such as agammaglobulinemia, where B cell maturation is arrested due to defective pre-BCR signaling.

IGLL1 antibodies are valuable tools in studying B cell biology and related pathologies. They are used to detect IGLL1 expression in research models, aiding in the identification of B cell developmental blocks or malignancies like B cell acute lymphoblastic leukemia (B-ALL), where aberrant IGLL1 expression may serve as a biomarker. Additionally, these antibodies contribute to understanding autoimmune disorders and immune reconstitution in transplant settings. Recent studies also explore IGLL1’s role in non-lymphoid tissues, hinting at broader functional implications. As therapeutic targets, IGLL1-directed agents are under investigation for modulating B cell-related diseases, though clinical applications remain exploratory. Overall, IGLL1 antibodies are pivotal in elucidating immune development and disease mechanisms.